Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Array Biopharma, now a wholly owned subsidiary of Pfizer
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Histologically or cytologically confirmed diagnosis of any advanced/metastatic solid tumor suitable for treatment with docetaxel.
Tumor recurred or progressed following at least one line of chemotherapy, except if no standard of care exists or if the patient refuses standard of care treatment.
Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0, 1 or 2.
Must be able to take and retain oral medications.
Other criteria exist.
You may not be if
Active concomitant malignancies.
Uncontrolled or symptomatic brain metastases (if a patient has brain metastases and is on steroids, the steroid dose must be stable for at least 30 days prior to study start).
Known positive serology for the human immunodeficiency virus (HIV), hepatitis B and/or hepatitis C.
Requiring intravenous (IV) alimentation.
Pregnancy or lactation.
Chemotherapy, anticancer immunotherapy, monoclonal antibodies or biologics within 21 days prior to first dose of study drug.
Anti-ErbB1 and/or ErbB2 targeted therapy or anticancer hormonal therapy within 14 days prior to first dose of study drug.
History of hypersensitivity to or intolerance of docetaxel.
